AKT1 and melanoma: In contrast, the activation or overexpression of an RTK, which usually activates both the MAPK and PI3K‐AKT‐mTOR signaling pathways, including EGFR, MET, PDGFRβ, and IGF1R, can exist in BRAF inhibitor‐resistant melanoma cells by activating PI3K‐AKT‐mTOR.42, 59, 69, 74, 76